AjjaiShivaramAlvaMD

Oncology • Ann Arbor, MI

Genitourinary Oncology, Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Alva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alva's full profile

Already have an account?

Office
1500 E Medical Center Dr
B1 Floor Cancer Recp D
Ann Arbor, MI 48109
Phone+1 734-647-8903

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2010
St Agnes HealthCareResidency, Internal Medicine, 2004 - 2007
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2000

Certifications & Licensure

MI State Medical License 2007 - 2025
IN State Medical License 2010 - 2013
TX State Medical License 2010 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases Start of enrollment: 2016 Apr 01
Terminated
Phase 2
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma Start of enrollment: 2016 Jun 01
Completed
Early Phase 1
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer Start of enrollment: 2017 Mar 16
Completed
Phase 1, Phase 2
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Start of enrollment: 2018 Jan 24
Terminated
Phase 2
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 May 31
Terminated
Phase 1
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer Start of enrollment: 2017 Dec 19
Active, not recruiting
Phase 1, Phase 2
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2019 Apr 11
Terminated
Phase 2
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations Start of enrollment: 2018 Dec 14
Active, not recruiting
Phase 2
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Nov 13
Recruiting
Phase 2
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Start of enrollment: 2020 Feb 20
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

4 citations
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jacob J Orme, Fadi Taza, Navonil De Sarkar, Alok K Tewari, Syed Arsalan Naqvi
European Urology Oncology. 2024-08-01
29 citations
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22
97 citations
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
Aaron M. Udager, Tzu-Ying Liu, Stephanie L. Skala, Martin J. Magers, Andrew S. McDaniel
Annals of Oncology. 2016-09-01

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma
Aaron M Udager, Andrew S Mcdaniel, Simpa S Salami, Samuel D Kaffenberger, Jeffrey S Montgomery, Alon Z Weizer, Zachery R Reichert, Ajjai S Alva, Arul M Chinnaiyan, Sco..., European Urology
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
Arul M Chinnaiyan, Ajjai S Alva, Clinical Cancer Research
Join now to see all

Lectures

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utiliza...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020